Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases

Ramya Ramaswami, Kathryn Lurain, Mark N. Polizzotto, Irene Ekwede, Kirsta Waldon, Seth M. Steinberg, Ralph Mangusan, Anaïda Widel, Adam Rupert, Jomy George, Priscila H. Gonçalves, Vickie A. Marshall, Denise Whitby, Hao-Wei Wang, Stefania Pittaluga, Elaine S. Jaffe, Richard F. Little, Thomas S. Uldrick, and Robert Yarchoan

1HIV & AIDS Malignancy Branch and 2Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; 3AIDS Monitoring Laboratory, Leidos Biomedical Research, Frederick, MD; 4Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Bethesda, MD; 5Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical, Frederick National Laboratory for Cancer Research, Frederick, MD; and 6Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Key Points

• Among people living with HIV, KSHV-MCD is underdiagnosed but treatable if identified, leading to 10-year survival of 71% in this cohort.
• KSHV-MCD can occur alone or with other KSHV-associated conditions, and the presence of concurrent PEL can impact survival.

Kaposi sarcoma (KS)-associated herpesvirus (KSHV)–associated multicentric Castleman disease (MCD) is a relapsing and remitting systemic lymphoproliferative disorder characterized by severe inflammatory symptoms most common among people living with HIV (PLWH). Patients with KSHV-MCD may present with concurrent KSHV-associated diseases, such as KS and/or primary effusion lymphoma (PEL). We evaluated clinical and immunologic characteristics, the effects of concurrent KSHV malignancies, and treatments from the largest prospective natural history study of participants with KSHV-MCD within the United States. Treatment options administered at investigator discretion included high-dose zidovudine with valganciclovir (AZT/VGC), rituximab, or rituximab with liposomal doxorubicin (R-Dox) during KSHV-MCD flares. Survival analyses and prognostic factors were explored for all participants. Sixty-two participants were enrolled, including 20 with KSHV-MCD alone, 34 with KSHV-MCD and KS, 1 with KSHV-MCD and PEL, and 7 with all KSHV-associated diseases. Forty-four percent of KSHV-MCD diagnoses were made at our institution. Forty-four participants received rituximab-based therapies, 20 of whom had maintenance AZT/VGC or interferon. Participants receiving R-Dox and then maintenance AZT/VGC had the highest 5-year progression-free survival (89%). Cytokine profiles during KSHV-MCD flares did not differ by the presence of concurrent KSHV-associated diseases. The 10-year survival was 71% (95% confidence interval [CI], 56% to 82%) for all participants. A concurrent diagnosis of PEL negatively impacted survival (PEL hazard ratio, 5.4; 95% CI, 1.8 to 16.8). KSHV-MCD is an underdiagnosed condition among PLWH, including those with KS. KSHV-MCD has an excellent prognosis with appropriate treatment. Physicians should be alert for patients with multiple KSHV diseases, which impact optimal treatment and survival outcomes. This study was registered at www.clinicaltrials.gov as #NCT00099073.

Introduction

Kaposi sarcoma (KS)–associated herpesvirus (KSHV), also known as human herpesvirus 8, causes 3 principal conditions: KS, primary effusion lymphoma (PEL), and a plasmablastic form of multicentric Castleman disease (MCD).1-3 KSHV-MCD is a rare relapsing and remitting B-cell lymphoproliferative disorder that most often develops in people living with HIV.4,5 This condition is associated with elevated...
cytokine levels, including interleukin-6 (IL-6) and IL-10, and production of a KSHV-encoded homolog of IL-6 (viral IL-6 [vIL-6]). Patients usually present with lymphadenopathy and inflammatory symptoms, including fever and night sweats. Laboratory abnormalities include cytopenias, hypoalbuminemia, hyponatremia, and elevated C-reactive protein (CRP). Clinicians may incorrectly attribute signs and symptoms of KSHV-MCD to HIV infection or other infective processes. Diagnosis of KSHV-MCD requires pathological confirmation from an involved lymph node. KSHV-MCD can progress to multiorgan dysfunction and is lethal if untreated, with a median survival of 2 years. Though KSHV-MCD can occur alone, patients can present with concurrent KS or PEL or all 3 conditions (KS, KSHV-MCD, and PEL) together.

The principal pathogenic cells in KSHV-MCD are KSHV-infected, λ-restricted plasmablasts, most commonly in the outer mantle zone or marginal zone of involved lymph nodes. A proportion of KSHV-infected cells express vIL-6 and sometimes express other KSHV lytic genes. KSHV-infected plasmablasts generally express OCT2, BLIMP1, and IRF4/MUM1 but lack PAX5, BCL6, and CD138. They are variably positive for CD20. Many symptoms and laboratory abnormalities associated with KSHV-MCD are caused by production of vIL-6 and increases in human IL-6 and IL-10.

While there are no approved therapies for KSHV-MCD, a number of agents and regimens have now been recommended by the National Comprehensive Cancer Network Guidelines. KSHV-MCD flares can be treated with rituximab, an anti-CD20 monoclonal antibody, which leads to resolution of the signs and symptoms associated with an acute flare in the vast majority of patients. Furthermore, rituximab may be used for subsequent KSHV-MCD flares. However, rituximab is associated with worsening of KS in 35% to 67% of individuals with concurrent KSHV-MCD and KS.

We developed a regimen combining rituximab and liposomal doxorubicin (R-Dox), a standard therapy for KS that also targets B cells, which led to responses in both KS and KSHV-MCD. Another treatment option we developed for KSHV-MCD is virus-activated cytotoxic therapy using high-dose zidovudine combined with valganciclovir (AZT/VGC). AZT and VGC are activated to toxic moieties by KSHV lytic genes (ORF21 and ORF36) and thus specifically target KSHV-MCD plasmablasts. Participants treated with oral AZT/VGC had a response rate of 86% with associated decreases in the KSHV viral load (VL), IL-6, IL-10, and CRP. Despite the treatment options available for KSHV-MCD, the risk of B-cell lymphoma, particularly PEL, remains high among patients with KSHV-MCD as compared with the general population. For patients with KSHV-MCD and PEL, available literature suggests that the simultaneous occurrence of PEL requires combination cytotoxic chemotherapy with curative intent. The cytokine profiles, outcomes, or prognostic implications of other concurrent KSHV-associated diseases in patients with KSHV-MCD are largely unknown and may be heterogeneous.

Here, we present the characteristics, treatment, and survival outcomes from the largest series of participants with HIV infection and KSHV-MCD in the United States. We also compared cytokine and KSHV levels of participants with KSHV-MCD alone, those with concurrent KSHV-MCD and KS, and those with all 3 KSHV-associated diseases to better understand the pathogenesis of these conditions.
Participants enrolled early in the study could receive optional consolidation therapy with maintenance interferon-α (IFN-α) or AZT/VGC following R-Dox. Participants with concurrent MCD+PEL±KS, and a few participants with particularly severe KSHV-MCD flares, were treated with dose-adjusted (DA)EPOCH-R (etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide, and rituximab), a multagent chemotherapy regimen often used for the treatment of HIV-associated non-Hodgkin lymphoma.29 (DA)EPOCH-R was administered alone or in combination with other agents in this study or on other ongoing protocols for 6 cycles. Participants were permitted to receive the same therapy for KSHV-MCD or a different treatment of subsequent flares. Participants received antiretroviral therapy and opportunistic infection prophylaxis in accordance with existing guidelines.30

Cytokines and KSHV VL

The KSHV VL per million peripheral blood mononuclear cells (PBMCs) was measured in DNA extracted from PBMCs by polymerase chain reaction using K6 primers.31 Measurement of serum levels of inflammatory cytokines (IFN-γ, IL-10, IL-12, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor-α [TNF-α]) was performed using the MSD 96-Well Multiarray Pro-inflammatory 10-plex assay (Meso Scale Discovery, Gaithersburg, MD). Cytokine levels were measured from samples obtained at the time of the first flare and remission on study entry and 4 weeks following treatment of MCD+PEL±KS participants.

Statistical considerations

Differences in baseline characteristics were evaluated using the Kruskal-Wallis test or Wilcoxon rank sum test for continuous variables and Mehta’s modification to the Fisher’s exact test for categorical variables. Analyses of the differences in cytokines between participants with MCD alone as compared with MCD+KS or MCD+PEL±KS were evaluated using the Wilcoxon rank sum test. Wilcoxon signed rank test was used to analyze the KSHV VL and cytokines from flare to remission/end of treatment. In view of the number of evaluations performed for cytokine analyses, a P value < .005 was considered statistically significant, and a P value between .005 and .05 was considered a strong trend. Univariate analyses of prognostic factors were studied using the Cox proportional hazard model with cytokines and other continuous variables dichotomized using the median values. Survival was evaluated by using the Kaplan-Meier method, and 2-sided log-rank tests were used to determine the statistical significance of differences between curves; where appropriate, Bonferroni correction was used to correct for multiple comparisons. As participants were able to move between therapy options, progression-free survival (PFS) was calculated from treatment initiation with a specific therapy to treat KSHV-MCD within this protocol (AZT/VGC, rituximab, or R-Dox [alone or with maintenance therapies]), until death or a subsequent MCD flare necessitating further treatment of participants with MCD alone or MCD+KS only irrespective of prior therapy. For overall survival, all-cause mortality was evaluated from diagnosis of MCD until death from any cause or censoring on 1 May 2020.

Results

Patient characteristics

Sixty-two participants (58 cisgender men and 4 cisgender women) with HIV and KSHV-MCD were enrolled between 2004 and 2019 (Table 1). The median age of all participants at the time of KSHV-MCD diagnosis was 44 years (range, 26-68 years). There were 20 participants with a diagnosis of MCD alone, 34 participants with MCD+KS, and 8 participants with MCD+PEL±KS (defined here as having PEL diagnosis within 12 months of MCD diagnosis). Among those with MCD+PEL±KS, 7 participants were diagnosed with all 3 conditions at the same time. Twenty participants (59%) with MCD+KS had T1 KS, whereas all participants with MCD+PEL±KS had stage T1 KS.

At study entry, the Eastern Cooperative Oncology Group (ECOG) performance status was 0-2 in 69% and ≥3 in 31% of all participants. With respect to HIV characteristics, the median time from HIV diagnosis to MCD diagnosis was 12.8 years for those with MCD alone, whereas among those with MCD+KS and MCD+PEL±KS, the time from HIV diagnosis to MCD was 2.8 years and 3.1 years, respectively (P = .002). All participants except 2 with MCD alone were on ART at the time of study entry. At MCD diagnosis the, median CD4 T-cell count among all participants was 180 cells/μL and the median HIV VL was <50 copies/mL. Both CD4 and HIV VL did not vary among the 3 patient groups.

Among all participants, 27 (44%) of all KSHV-MCD diagnoses had not been made on referral and were only made upon evaluation at our center. Those with KSHV-MCD alone were often referred for lymphadenopathy, pancytopenia, fevers, and/or night sweats; referrers frequently were considering the possibility of lymphoma. Nearly all participants with MCD+PEL±KS and MCD+KS presented with KS and/or effusions in addition to lymphadenopathy, fevers, and night sweats. In these cases, referrers were often concerned about progressive KS despite systemic KS treatment and well-controlled HIV. In 17 out of the 27 participants diagnosed with KSHV-MCD at our center (including 11 with concurrent KS), KSHV-MCD was diagnosed from a lymph node biopsy performed at our center. In the remaining 10 participants, review by NCI pathologists identified a diagnosis of KSHV-MCD on a biopsy performed elsewhere in which KSHV-MCD had not been diagnosed. Of the 35 participants with MCD diagnosed before referral, 20 (57% or 32% of all participants) had prior rituximab therapy at study entry, including 55% of those with MCD alone, 20% of those with MCD+KS, and 25% of those with MCD+PEL±KS (P = .04).

KSHV-MCD protocol treatments and PFS

Forty-four participants (71%) were administered ≥1 treatment for KSHV-MCD over the course of their enrollment in this protocol, and 8 additional participants with concurrent PEL received infusional (DA)EPOCH-R therapy either within this study or within another ongoing investigational study (NCT02911142). Two participants with severe KSHV-MCD and multiorgan dysfunction requiring admission to the intensive care unit were administered (DA)EPOCH-R. Among those with either MCD alone or concurrent KS, 17 participants were initially treated with AZT/VGC and 8 participants received rituximab alone (Table 2). Thirty-six participants received R-Dox chemotherapy; this was initial therapy in 61% of cases, and the majority of participants treated with this regimen had MCD+KS. Participants who initially received R-Dox alone or with maintenance therapy on study had a median hemoglobin 9.3 g/dL and median CRP 108 mg/L, and 27% of these patients had an ECOG 4 (supplemental Table 3),
highlighting the severity of their illness. Twenty participants had maintenance therapy with either AZT/VGC or IFN-α following R-Dox (Table 2). The median duration of treatment leading to remission was 5 months for participants receiving AZT/VGC and 2 months for those receiving R-Dox alone. Those treated with R-Dox and IFN-α received a median of 7 months therapy (including a median of 4 months maintenance), and those treated with R-Dox received a median of 11 months therapy (including a median of 9 months maintenance).

Those who received AZT/VGC had a 26% 5-year PFS (95% confidence interval [CI], 8% to 49%) (Table 2). Participants who received R-Dox without maintenance had a 62% 5-year PFS (95% CI, 23% to 85%), while participants who received R-Dox and maintenance AZT/VGC had a 5-year PFS of 87% (95% CI, 39% to 98%; supplemental Figure 1). Comparing the other KSHV-MCD regimens to AZT/VGC and adjusting for multiple comparisons, rituximab alone and R-Dox with or without maintenance had higher 5-year PFS (Table 2). Of the 17 participants initially treated with AZT/VGC, 4 participants required no further treatment of KSHV-MCD, and 13 participants were subsequently treated with rituximab alone (2 participants) or R-Dox with maintenance regimens for a subsequent flare.

Following rituximab-based treatment on the study, 28 of 44 participants experienced no further KSHV-MCD flare. Four participants had 1 subsequent flare, and 1 patient had 2 flares; all of these resolved with repeated treatment with R-Dox. Twelve participants with MCD1 KS treated with rituximab alone or R-Dox resulting in KSHV-MCD remission received additional treatment of KS with liposomal doxorubicin, paclitaxel, or experimental protocols within our group due to stable or progressive KS. Overall, 7 participants with MCD1 KS had KS progression during or soon after therapy for MCD. One participant had progressive KS during R-Dox; in another case, KS progression was seen during AZT/VGC maintenance; and in the remaining 5 participants, KS progression was noted within 6 weeks of rituximab cessation.

Table 1. Baseline characteristics of all patients and those with KSHV-MCD alone and concurrent KSHV-associated diseases

| Baseline characteristics                        | All patients (N = 62) | MCD alone (n = 20) | MCD with concurrent KS (n = 34) | MCD with concurrent PEL+KS (n = 8) | P* |
|------------------------------------------------|----------------------|-------------------|---------------------------------|-----------------------------------|----|
| Age at MCD diagnosis, median (IQR), y           | 44 (38-54)           | 46 (44-54)        | 41 (46-48)                      | 46 (29-56)                       | .07|
| Sex, n (%)                                      |                      |                   |                                 |                                   |    |
| Cisgender male                                  | 58 (94)              | 19 (95)           | 31 (91)                         | 8 (100)                          | 1.00|
| Cisgender female                                | 4 (6)                | 1 (5)             | 3 (9)                           | 0                                |    |
| Race, n (%)                                     |                      |                   |                                 |                                   | .87|
| White                                           | 31 (50)              | 10 (50)           | 16 (47)                         | 5 (62)                           |    |
| Hispanic                                        | 5 (8)                | 2 (10)            | 3 (9)                           | —                                |    |
| Black                                           | 16 (26)              | 6 (30)            | 7 (20)                          | 3 (38)                           |    |
| African immigrant                               | 7 (11)               | 2 (10)            | 5 (15)                          | —                                |    |
| Other                                           | 3 (5)                | —                 | 3 (9)                           | —                                |    |
| ECOG performance status, n (%)                  |                      |                   |                                 |                                   | .05|
| 0-2                                             | 43 (69)              | 17 (85)           | 23 (88)                         | 3 (38)                           |    |
| ≥3                                              | 19 (31)              | 3 (15)            | 11 (32)                         | 5 (62)                           |    |
| HIV characteristics at MCD diagnosis            |                      |                   |                                 |                                   |    |
| Time from HIV diagnosis to MCD diagnosis, median (IQR), y | 4.5 (0.7, 11.5)      | 12.8 (3.9, 18.9)  | 2.8 (0.4, 7)                    | 3.1 (0.3, 8.4)                   | .002|
| CD4 T-cell count, median (IQR), cells/μL        | 180 (100, 302)       | 227 (114, 500)    | 126 (88, 248)                   | 252 (180, 371)                   | .14 |
| HIV viral load at MCD diagnosis, median (IQR), copies/mL | <50 (<50, 2599)     | <50 (<50, 563)    | 376 (<50, 2599)                 | 3648 (<50, 30773)                | .77 |
| On ART, n (%)                                   | 60 (97)              | 18 (90)           | 34 (100)                        | 8 (100)                          | .20 |
| KSHV-MCD characteristics                        |                      |                   |                                 |                                   |    |
| Rituximab therapy prior to enrollment, n (%)    | 20 (32)              | 11 (55)           | 7 (20)                          | 2 (25)                           | .04 |
| Number of flares treated, median (range)        | 2 (1-5)              | 2 (1-5)           | 2 (1-5)                         | 2 (1-4)                          | .17 |
| Diagnosis of MCD made at NCI, n (%)             | 27 (44)              | 7 (35)            | 15 (44)                         | 5 (63)                           | .39 |
| KS characteristics                              |                      |                   |                                 |                                   |    |
| Any KS, n (%)                                   | 41 (66)              | —                 | 34 (100)                        | 7 (88)                           | .19 |
| T1 stage KS, n (%) of all patients with KS      | 27 (66)              | —                 | 20 (59)                         | 7 (100)                          | .22 |
| Time from KS diagnosis to MCD, median (IQR), mo | 1.3 (0, 40)          | —                 | 0.4 (0, 20)                     | 40 (0, 60)                       | .3  |
| Prior chemotherapy for KS, n (%)                | 21 (34)              | —                 | 16 (50)                         | 5 (50)                           | 1.00|
| Prior chemotherapy for KS, median (range)       | 1 (1-3)              | —                 | 1 (0-3)                         | 1 (0-2)                          | 1.00|

ART, antiretroviral therapy.

*P values comparisons of 3 groups were determined by Mehta’s modification to Fisher’s exact test and by exact Kruskal-Wallis or exact Wilcoxon rank sum test as appropriate.
Laboratory, cytokine, and KSHV-VL profiles in KSHV-MCD and concurrent KSHV-associated conditions

Laboratory findings that are characteristic of MCD flares, including anemia, thrombocytopenia, hypoalbuminemia, and elevated CRP, were seen among all participants (Table 3). Seven cytokines (IFN-γ, IL-10, IL-1β, IL-4, IL-6, IL-8, and TNF-α) were elevated among all participants with MCD with or without concurrent KSHV-associated diseases during flares when compared with median normal serum values. There were no statistically significant differences in any of the cytokine or laboratory values during flares between MCD alone as compared with MCD + KS or MCD + PEL ± KS (Table 3). Among all participants, 6 cytokines (IFN-γ, IL-10, IL-13, IL-4, IL-6, and TNF-α) decreased significantly from flare to remission/end of treatment (supplemental Table 4). Interestingly, while IL-13 levels remained within normal range during flares, levels decreased from flare to remission. Among the cytokines most associated with KSHV-MCD pathogenesis, there was a significant decrease from flare to remission in IL-10, IL-6, and IFN-γ for participants with MCD + KS or MCD alone. However, these changes were not seen among those with MCD + PEL ± KS at the end of treatment (Figure 1).

The median circulating KSHV VL among all participants during flares was 3.8 log10 copies/10⁶ PBMCs (interquartile range [IQR], 3.0; 5.1 log10 copies/10⁶ PBMCs), which decreased significantly following remission (P < .0001; supplemental Table 4; Figure 2). There was no difference in the KSHV-VL levels during flares between participants with KSHV-MCD alone compared with participants with either MCD + KS or MCD + PEL ± KS (Table 3). KSHV-VL levels decreased substantially from flare to remission for participants with MCD alone (P = .0005) and MCD + KS (P < .0001), but not from flare to end of treatment of those with MCD + PEL ± KS (Figure 2).

Survival outcomes and prognostic factors

The median follow-up time for all participants on this study was 5.9 years, and over the course of this study, 16 participants died. The 10-year overall survival for all participants was 71% (95% CI, 56% to 82%; Figure 3A). There were statistically significant differences in the comparisons among the 3 subgroups with respect to overall survival (log-rank P = .0041; Figure 3B). A concurrent diagnosis of PEL negatively impacted survival (hazard ratio [HR], 5.4; 95% CI, 1.8 to 16.8; P = .003); participants with MCD + PEL ± KS had a 5-year overall survival of 38% (95% CI, 9% to 67%), and 10-year survival was not reached. Among those with MCD alone, 5-year overall survival was 90% (95% CI, 66 to 97), and the 10-year survival was 73% (95% CI, 42% to 90%); for those with MCD + KS, the 10-year survival was 81% (95% CI, 63% to 91%). In the follow-up period, 2 participants with MCD + KS (both initially treated with R-Dox) were diagnosed with PEL 6 and 12 years after their MCD diagnosis. Both participants are alive more than 2 years after treatment using (DA)EPOCH-R with lenalidomide (NCT02911142).

In addition to concurrent diagnosis of PEL, concurrent stage T1 KS (HR, 3.0; 95% CI, 1.1 to 8.4; P = .035) also impacted overall survival (Table 4). However, those with T1 KS without PEL did not have increased mortality (HR, 1.5; 95% CI, 0.6 to 4.3; P = .4), suggesting that most of the effect of T1 KS on survival was due to its association with PEL. None of the inflammatory cytokine levels measured during flares were prognostic overall, nor was KSHV-VL.

Of the 16 participants who died, 11 died of their KSHV-associated diseases (supplemental Table 5). Among participants with MCD + KS, 2 participants died of pulmonary KS despite combination of rituximab and chemotherapy for KS, and 2 died of multiorgan failure. All 5 deaths in participants with PEL were from refractory disease. Four participants (2 with MCD alone and 2 with MCD + KS) died >5 years after their treatment from other causes; 1 patient died of pancreatic cancer, 1 patient died of a hyperglycemic state due to uncontrolled diabetes mellitus, and 2 participants died at home of unclear causes; an autopsy could not be performed in these cases.

Discussion

This long-term study of a US-based cohort of 62 participants KSHV-MCD provides important observations about the pathogenesis and natural history of KSHV-MCD, the cytokine

---

**Table 2. Treatments received on study for KSHV-MCD alone or with concurrent KS, median duration of treatment, and 5-year PFS**

| Treatment | All patients treated | MCD alone | MCD with concurrent KS | As first regimen on protocol (%) | Median duration of treatment leading to KSHV-MCD remission, mo | 5-y PFS, % (95% CI) | P† |
|-----------|---------------------|-----------|------------------------|---------------------------------|---------------------------------------------------------------|-------------------|-----|
| AZT/VGC   | 17                  | 8         | 11                     | 17 (100)                        | 5                                                             | 26 (8, 49)        | —   |
| Rituximab alone | 8 | 6         | 2                      | 5 (63)                          | 1                                                             | 71 (26, 92)       | .03 |
| Rituximab and liposomal doxorubicin | 36 | 7         | 29                     | 22 (61)                         | 5                                                             | 73 (53, 86)       | —   |
| No maintenance | 16 | 1         | 15                     | 13 (81)                         | 2                                                             | 62 (23, 85)       | .02 |
| AZT/VGC maintenance | 10 | 5         | 5                      | 7 (70)                          | 11 (9 mo of AZT/VGC in maintenance phase) | 87 (39, 98)       | .0009 |
| IFN-α maintenance | 10 | 1         | 9                      | 2 (20)                          | 7 (4 mo of IFN-α in maintenance phase) | 70 (33, 89)       | .01 |

*Values shown are the number of patients treated as the first regimen on protocol; †% indicates first regimen on the protocol among all patients treated with that regimen.
P-values are log-rank tests of PFS comparing AZT/VGC with other KSHV-MCD regimens used that are adjusted for multiple comparisons (Bonferroni test). Patients who received (DA)EPOCH±R (8 patients) are not included in this table.
In general, KSHV-MCD outcomes in this study suggested lower rates of PEL onset in this cohort. These 2 individuals with MCD was 24%. Among participants with KSHV-MCD, elevated KSHV-VL levels, TNF-α, IL-10, IL-6, and v-IL6 were observed in an earlier study of 21 participants within this KSHV-MCD cohort. In addition to KSHV-VL, IFN-γ, TNF-α, IL-10, and IL-6, we also noted statistically significant decreases in IL-4 and IL-13 from flares to remission. These cytokines implicate the potential role of the JAK-STAT pathway in KSHV-MCD, which is activated by IL-4, IL-6, IL-8, and TNF-α. We did not identify distinct cytokine or KSHV-VL differences between different groups during flares that would aid diagnosis of concurrent KSHV diseases. Having >1 KSHV-associated disease did not significantly alter the flare cytokine profiles. These similarities contribute to making the diagnosis of these disorders challenging and further reinforce the view that these conditions are part of a spectrum of KSHV-associated diseases with similar cytokine dysregulation.

Compared with normal values, 7 cytokines (IFN-γ, IL-10, IL-1β, IL-4, IL-6, IL-8, and TNF-α) were increased during flares in all participants with KSHV-MCD. Elevated KSHV-VL levels, TNF-α, IL-10, IL-6, and v-IL6 were observed in an earlier study of 21 participants within this KSHV-MCD cohort. In addition to KSHV-VL, IFN-γ, TNF-α, IL-10, and IL-6, we also noted statistically significant decreases in IL-4 and IL-13 from flares to remission. These cytokines implicate the potential role of the JAK-STAT pathway in KSHV-MCD, which is activated by IL-4, IL-6, and v-IL6. We did not identify distinct cytokine or KSHV-VL differences between different groups during flares that would aid diagnosis of concurrent KSHV diseases. Having >1 KSHV-associated disease did not significantly alter the flare cytokine profiles. These similarities contribute to making the diagnosis of these disorders challenging and further reinforce the view that these conditions are part of a spectrum of KSHV-associated diseases with similar cytokine dysregulation.

This study also highlights the importance of considering a diagnosis of KSHV-MCD in people living with HIV in populations with a high KSHV seroprevalence or among patients with HIV-associated KS who have unexplained inflammatory syndromes. Forty-four percent of all KSHV-MCD diagnoses were KSHV-associated diseases, and long-term responses to various therapies. The long-term outcomes were generally favorable, with an overall survival of 71% at 10 years for all participants. Deaths in this cohort were most commonly due to a treatment-refractory KSHV-associated malignancy. In these analyses, a concurrent diagnosis of PEL was associated with increased mortality; increased mortality in patients with T1 KS was driven by its association with PEL. Oksenhendler et al estimated that the 2-year probability of developing non-Hodgkin lymphoma among individuals with MCD was 24%. Among participants with MCD alone or MCD+KS, only 2 of the 54 participants developed PEL 6 and 12 years after their initial MCD diagnosis, suggesting lower rates of PEL onset in this cohort. These 2 individuals and the majority of participants on the study received rituximab alone or in combination with chemotherapy, which is hypothesized to decrease the risk of lymphoma onset in this population. In general, KSHV-MCD outcomes in this study are similar to retrospective analyses from European centers. The 5-year survival among participants with KSHV-MCD and a diagnosis of PEL was 38%, which is better than earlier reports in the literature.

Comparison between KSHV-MCD therapies demonstrated that participants treated with R-Dox and maintenance AZT/VGC had the highest 5-year PFS and that participants with R-Dox, with or without maintenance had better PFS than AZT/VGC given as initial therapy. A limitation of this comparison is that these therapies were not randomized and many had received prior therapy. However, the participants treated with R-Dox tended to be sicker than those treated with AZT/VGC. The overall benefit of maintenance after rituximab therapy with AZT/VGC is not clear at this point; while this led to higher 5-year PFS, this option needs to be weighed against the potential toxicities associated with AZT/VGC and the high salvage rates following retreatment with rituximab alone.

| Flare laboratory findings | Normal range or normal median (range)* | All patients | MCD alone | MCD with concurrent KS | MCD with concurrent PEL ± KS | P† |
|---------------------------|----------------------------------------|--------------|-----------|------------------------|-----------------------------|----|
| Hemoglobin, g/dL          | 13.7-17.5 (8.0, 11.5)                  | 9.5 (8.0, 11.5) | 10.3 (8, 11.3) | 9.5 (7.9, 11.5) | .83 | 9.2 (8.4, 11.5) | .97 |
| Platelets, ×10^9/μL       | 161-347 (117 [9, 253])                | 90 (37, 344) | 118 (70, 164) | .93 | 195 (55, 347) | .94 |
| Albumin, g/dL             | 3.5-5.2 (2.2, 3.3)                    | 2.7 (2.1, 3.4) | 2.9 (2.4, 3.4) | .67 | 2.5 (1.5, 3.0) | .24 |
| CRP, mg/mL                | 0-4.99 (88.1 [19.3, 144])             | 97 (27.1, 195) | 101.2 (14.5, 144) | .56 | 70.6 (50, 88.1) | .38 |

Flare, median (IQR)

- IFN-γ, pg/mL: 3.77 (0.64-14.4) vs. 32.9 (15.6, 139.6) vs. 30.9 (14.6, 97) vs. 34.3 (18.4, 166) vs. .74 vs. 26.0 (14.6, 94.3) vs. .79
- IL-10, pg/mL: 0.2 (0.06-3.08) vs. 100.8 (18.7, 730) vs. 265.6 (44.4, 1290) vs. 92.6 (9.2, 730) vs. .36 vs. 171.6 (39, 958.4) vs. .79
- IL-12, pg/mL: 0.29 (0.26-0.38) vs. 0.2 (0.1, 0.3) vs. 0.2 (0.1, 0.5) vs. 0.1 (0.1, 0.3) vs. .42 vs. 0.2 (0.1, 0.3) vs. .46
- IL-13, pg/mL: 1.65 (0.6-2.78) vs. 0.5 (0.1, 0.9) vs. 0.6 (0.1, 1) vs. 0.5 (0.1, 1) vs. .79 vs. 0.5 (0.1, 0.8) vs. .53
- IL-1β, pg/mL: 0.16 (0.11-24.3) vs. 0.3 (0.2, 0.6) vs. 0.3 (0.1, 0.6) vs. 0.3 (0.2, 0.6) vs. .88 vs. 0.4 (0.2, 0.6) vs. .88
- IL-2, pg/mL: 0.52 (0.22-2.68) vs. 0.6 (0.4, 0.9) vs. 0.6 (0.4, 1) vs. 0.4 (0.3, 0.9) vs. .88 vs. 0.8 (0.4, 1.2) vs. .42
- IL-4, pg/mL: Not detectable (0.06, 0.14) vs. 0.1 (0.06, 0.20) vs. 0.08 (0.05, 0.1) vs. 0.27 (0.07, 0.06, 0.1) vs. .32
- IL-6, pg/mL: 0.47 (0.16-27.2) vs. 8 (3.8, 25.8) vs. 19 (4.2, 56.3) vs. 6.8 (3.0, 15.9) vs. .12 vs. 8.3 (6.6, 31.0) vs. .74
- IL-8, pg/mL: 0.47 (0.16-27.2) vs. 63.1 (19.3, 107.4) vs. 86.1 (18.7, 157.9) vs. 50 (19.3, 91.3) vs. .32 vs. 78.5 (28.8, 117.1) vs. .65
- TNF-α, pg/mL: 0.36 (0.10-1.75) vs. 9 (0.5, 12.6) vs. 9.4 (6.2, 12.4) vs. 8.7 (7.1, 13.1) vs. .89 vs. 8.4 (6.5, 16.4) vs. .79
- KSHV-VL, log_{10} copies/10^6 PBMCs: NA vs. 3.8 (3.0, 5.1) vs. 3.9 (3.0, 5.2) vs. 3.9 (3.2, 5.2) vs. .78 vs. 3.7 (1.1, 4.2) vs. .65

Table 3. Laboratory findings and cytokines of interest between diseases during first KSHV-MCD flare on protocol.

*For cytokines, median and normal range are from 27 normal serum human samples tested in the proinflammatory panel 1 (human) kit. †Normal median (range) All patients MCD alone MCD with concurrent KS MCD with concurrent PEL ± KS P†.

NA, not available.

1P values are for comparisons with MCD alone.
disorder. From an HIV perspective, >95% of the participants were on ART at the time of an MCD diagnosis and were virologically suppressed, with a CD4 count >100. In the present study, 66% of KSHV-MCD participants had KS, which is consistent with previous studies showing that 54% to 72% of KSHV-MCD participants have concurrent KS.9,12 However, it is unclear how many patients with KS have concurrent MCD, and this requires further study. While KS is a prominent cutaneous tumor that is generally not difficult to recognize, the diagnosis of KSHV-MCD (with or without PEL) requires a high level of suspicion, invasive diagnostic procedures, and specialist pathology review. Moreover, the inflammatory signs and symptoms of KSHV-MCD can mimic a number of other diseases that occur in people living with HIV, such as lymphoma, uncontrolled HIV, or infections, such as tuberculosis. Based on our experience, it is particularly important to consider KSHV-MCD in patients with HIV infection with or without KS who experience fevers, fatigue, effusions, edema, and laboratory abnormalities such as cytopenias, hypoalbuminemia, CRP elevations, or circulating KSHV levels. Additionally, concurrent PEL should be considered if these symptoms (particularly effusions) persist despite treatment of KSHV-MCD with rituximab-based therapies.

These study findings may be applicable beyond the United States. Eleven percent of the participants were from sub-Saharan Africa. While KSHV-infection and KS are common in many parts of sub-Saharan Africa,9 there are very few reported cases of KSHV-MCD in this region, and it is likely that many cases are misdiagnosed as tuberculosis or other infections. Where KSHV-MCD has been diagnosed in sub-Saharan Africa, patients presented with severe symptoms, and high mortality rates were reported.39,40 This reinforces the need for physicians to look for KSHV-MCD and other KSHV-associated diseases in systemically unwell patients with concurrent HIV infection.
This is the largest single-center cohort of participants treated in the United States for KSHV-MCD with or without other KSHV-associated diseases and the first to compare patients with KSHV-MCD alone and concurrent KSHV-associated diseases. A possible limitation of this study is referral bias, as some of these participants were treated in other institutions for KSHV-MCD or KS prior to referral, which may have impacted our observations of the frequency of comorbid KSHV-associated diseases, cytokine profiles, or survival outcomes. Furthermore, the treatments offered for KSHV-MCD in this study were not randomized; therefore, differences in treatment-specific PFS outcomes should be considered hypothesis generating. Despite these limitations, this study conducted over a 16-year period provides valuable insights on the pathogenesis of KSHV-MCD, PEL, and KS.

In summary, KSHV-MCD remains an important and under-diagnosed condition among people living with HIV on ART. It often coexists with other KSHV-associated diseases, which can pose challenges in diagnosis and therapy. A high index of suspicion and proper diagnosis of KSHV-MCD and associated diseases is important, as these patients can have a good prognosis if appropriately treated.
Table 4. Univariate Cox proportional hazard model for overall survival

| Variable                                      | HR (95% CI) | P     |
|------------------------------------------------|-------------|-------|
| Age (above vs below median)                   | 1.8 (0.7-5.0) | .25   |
| CD4 count (<100 vs ≥100)                      | 0.5 (0.2-1.4) | .18   |
| HIV VL (<100 vs ≥100)                         | 1.3 (0.3-5.3) | .70   |
| Concurrent KS                                 | 1.8 (0.6-5.7) | .30   |
| Concurrent T1 KS                              | 3.0 (1.1-8.4) | .035  |
| T1 KS without PEL                             | 1.5 (0.6-4.3) | .40   |
| Concurrent PEL                                | 5.4 (1.8-16.8) | .003  |

Cytokines (above vs below median), pg/mL

- IFN-γ: 0.7 (0.3-1.9) .50
- IL-10: 0.8 (0.3-2.1) .60
- IL-12: 1.1 (0.4-3.0) .86
- IL-13: 1.0 (0.4-2.9) .93
- IL-1β: 0.7 (0.3-2.0) .52
- IL-2: 1.5 (0.5-4.3) .41
- IL-4: 1.4 (0.5-4.0) .51
- IL-6: 2.1 (0.7-6.2) .17
- IL-8: 1.1 (0.4-3.1) .85
- TNF-α: 0.9 (0.3-2.5) .83

Acknowledgments

The authors thank the individuals who volunteered for this study and their families. They thank the nurses, physicians, and patient care and clinical research support staff at the NCI and the National Institutes of Health Clinical Center, as well as the physicians who referred participants. They also thank Randy Stevens and other members of the Leidos AIDS Monitoring Laboratory.

This work was supported by the Intramural Research Program of the NCI, National Institutes of Health, and in part by the Intramural Program of the NCI, National Institutes of Health, Department of Health, and Human Services. This project has also been funded in part with federal funds from the NCI, National Institutes of Health and HHSN261200800001E.

References

1. Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. *N Engl J Med*. 2018;378(11):1029-1041.
2. Cesaran E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. *Nat Rev Dis Primers*. 2019;5(1):9.
3. Chang Y, Cesaran E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. *Science*. 1994;266(5192):1865-1869.
4. Oksenhendler E, Duarte M, Soulair J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. *AIDS*. 1996;10(1):61-67.
5. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. *Acta Oncol*. 2004;43(8):698-704.
6. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. *Blood*. 2001;97(8):2526-2527.
7. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. *Blood*. 2013;122(26):4189-4198.
8. Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. *Blood*. 2014;124(24):3544-3552.

Authorship

Contribution: R.F.L., T.S.U., M.N.P., and R.Y. designed the study; A.W., I.E., R.M., V.A.M., D.W., K.W., A.R., J.G., and R.R. collected and analyzed the data; E.S.J., H.-W.W., and S.P. confirmed the diagnosis of MCD by pathology; I.E., R.M., A.W., K.W., P.H.G., T.S.U., R.R., K.L., R.F.L., M.N.P., and R.Y. cared for the participants on the study; S.M.S. analyzed data and provided statistical support; and R.R. and R.Y. wrote the manuscript.

Conflict-of-interest disclosure: R.R., T.S.U., K.L., and R.Y. report receiving research support from Celgene through a cooperative research and development agreement (CRADA) at the NCI. R.R., T.S.U., K.L., and R.Y. report receiving a drug for a clinical trial from Merck through a CRADA at the NCI. R.R., K.L., and R.Y. report receiving a drug for a clinical trial from EMD-Serono through a CRADA at the NCI. R.Y. reports receiving a drug for a clinical trial from Fred Hutchinson Cancer Research Center. T.S.U., R.Y., and D.W. are co-inventors on US Patent 10,001,483 entitled “Methods for the treatment of Kaposi’s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers.” R.Y. is also a coinventor on patents on a peptide vaccine for HIV and the treatment of Kaposi sarcoma with IL-12, and an immediate family member of R.Y. is a co-inventor on patents related to internalization of target receptors, KSHV vIL-6, and the use of calreticulin and calreticulin fragments to inhibit angiogenesis. All rights, title, and interest to these patents have been or should by law be assigned to the US Department of Health and Human Services; the government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). The remaining authors declare no competing financial interests.

ORCID profiles: R.R., 0000-0001-5709-4675; K.L., 0000-0002-5794-7292; S.P., 0000-0001-7688-1439; E.S.J., 0000-0003-4632-0301; R.Y., 0000-0002-3057-1395.

Correspondence: Ramya Ramaswami, HIV/AIDS Malignancy Branch, Center for Cancer Research, 10 Center Dr, 6N106, Bethesda, MD 20892; e-mail: ramya.ramaswami@nih.gov.
9. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116(22):4415-4421.
10. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96(6):2069-2073.
11. Lurain K, Polizzotto MN, Aleman K, et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 2019;133(16):1753-1761.
12. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331-2336.
13. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000;156(3):743-749.
14. Du M-Q, Liu H, Dass TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM λ) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97(7):2130-2136.
15. Chadburn A, Hyjek EM, Tam W, et al. Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV-infected individuals with Kaposi sarcoma-associated herpesvirus-positive multicentric Castleman disease. Blood. 2015;125(23):3509-3513.
16. Hoffmann C, Schmid H, Müller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118(13):3499-3503.
17. Lurain K, Yarchoan R, Udlick T. Treatment of kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):75-88.
18. Tagawa T, Gao S, Koparde VN, et al. Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. Proc Natl Acad Sci USA. 2018;115(50):12805-12810.
19. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus infected multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25(22):3350-3356.
20. Dalla Fia P, Pinato D, Roe J, Naresh K, Nelson M, Bower M. Relapse of multicentric Castlemans disease following Rituximab based therapy in HIV-positive patients. Blood. 2017;130(6):996-997.
21. Davis DA, Rinderknecht AS, Zoeteweij JP, et al. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood. 2001;97(10):3244-3250.
22. Gustafson EA, Schinazi RF, Fingeroth JD. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol. 2000;74(2):684-692.
23. Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol. 1999;73(6):4786-4793.
24. Udlick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus ganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977-6986.
25. Chadburn A, Said J, Gratzinger D, et al. HHV8/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH/EAHP Workshop Report–part 3. Am J Clin Pathol. 2017;142(2):171-187.
26. In: Sverdlov SH, Campo E, Harris NL, eds., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours, Lyon, France: International Agency for Research on Cancer; 2017.
27. Ramaswami R, Lurain K, Peer CJ, et al. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2020;135(25):2316-2319.
28. Cheson BD, Fisher RI, Barrington SF, et al; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
29. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609-e617.
30. Kaplan JE, Benson C, Holmes KK, et al; Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
31. Udlick T, Polizzotto MN, Aleman K, Woyill KM, Marshall V, Whitby D, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124(24):3544-3552.
32. Meso Scale Diagnostics. Proinflammatory Panel 1 (Human). 2020.
33. Boulanger E, Gérard L, Gabbarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372-4380.
34. Boulanger E, Gérard L, Gabbarre J, et al. Prognostic factors and outcome of human herpesvirus 8 (KSHV/HHV-8)-associated primary effusion lymphoma (PEL) in patients with AIDS. Blood. 2004;104(11):2286.
35. Nan Y, Wu C, Zhang Y-J. Interplay between janus kinase/signal transducer and activator of transcription signaling activated by type I interferons and viral antagonism. Front Immunol. 2017;8:1758.
36. Herrero C, Hu X, Li WP, et al. Reprogramming of IL-10 activity and signaling by IFN-γ. J Immunol. 2003;171(10):5034-5041.
37. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105(6 Pt 1):1063-1070.
38. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. A Kaposi’s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem. 1997;272(31):19625-19631.

39. Gopal S, Liomba NG, Montgomery ND, et al. Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi. J Int AIDS Soc. 2015;18(1):20122.

40. Gonçalves PH, Uldrick TS, Yarchoan R. HIV-associated Kaposi sarcoma and related diseases. AIDS. 2017;31(14):1903-1916.